REAGAN-UDALL FOUNDATION for the Food and Drug Administration

Expanded Access: Insights & Resources

Virtual Public Webinar

Tuesday, August 18, 2026

Speaker Biographies

Grace Graham, MPP
Deputy Commissioner for Policy, Legislation, and International Affairs, FDA

Grace Graham is the Deputy Commissioner for Policy, Legislation, and International Affairs. In this role, she leads the Office of Policy, Legislation, and International Affairs (OPLIA), which serves as the FDA's focal point for engagement with the U.S. Congress, the Administration, global counterparts and partners, and state, local, territorial, and tribal policymakers.

Immediately before coming to the FDA, Grace served as Chief Health Counsel for the Energy and Commerce Committee (E&C) in the U.S. House of Representatives, where she worked on the 2022 User Fee Reauthorization and other health care matters under the scope of the committee. Prior to that, Mrs. Graham served as Health Policy Director for the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP), working on User Fee Legislation, 21st Century Cures laws, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act, and other health care legislation.

Grace has a Master of Public Policy and Health Policy, as well as a Bachelor of Science in Biomedical Engineering from the University of Virginia.

Rihanna Miller, JD
Regulatory Counsel, Office of Medical Policy, Center for Drug Evaluation and Research, FDA

Rihana Miller serves regulatory counsel in the Office of Medical Policy within FDA's Center for Drugs Evaluation and Research where she leads multidisciplinary working groups to develop guidance documents and regulations. Rihana earned her bachelor's degree from the University of California, Riverside, and her law degree from American University Washington College of Law.

Alison Bateman-House, PhD, MA, MPH
Associate Professor, NYU Grossman School of Medicine

Alison Bateman-House, PhD, MPH, MA is Associate Professor, Section of Medical Ethics, at NYU Grossman School of Medicine. Her scholarship explores ethical and policy concerns at the intersection of human subjects research, drug development and regulation, the social history of patient advocacy, and the construction of knowledge. Bateman-House chairs two academic multi-stakeholder groups. The first, the Working Group on Compassionate Use & Preapproval Access (CUPA), focuses on ethical issues concerning patient access to investigational medical products. The second, the Pediatric Gene Therapy & Medical Ethics (PGTME) Working Group, addresses ethical issues in the development and use of genetic interventions in pediatric patients and populations. Additionally, Bateman-House is PI of the NYU/Johnson & Johnson Compassionate Use Advisory Committee (CompAC), winner of the Reagan-Udall Foundation for the FDA's 2019 Innovation Award.

Mitchell Chan, PharmD, MSDA, BCPS
Clinical Analyst & Team Lead, Oncology Center of Excellence, FDA

Commander Mitchell Chan is a Clinical Analyst and Team Lead in the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence's Project Facilitate and has been a part of Project Facilitate since its launch. CDR Chan's career started as a clinical pharmacist in the Indian Health Service in New Mexico. He started at the FDA as a Regulatory Health Project Manager, managing drug approvals for breast, gynecologic/supportive care and genitourinary indications. As a Clinical Analyst with Project Facilitate, he performs clinical reviews of expanded access applications and manages the Project Facilitate Call Center. As a USPHS commissioned officer, CDR Chan has deployed to multiple responses such as COVID-19, hurricanes, and other humanitarian missions. He has earned his Bachelor of Science in General Science from Oregon State University, his Doctor of Pharmacy degree from the University of New England College of Pharmacy, completed a PGY1 Pharmacy Practice Residency focused on critical care and emergency medicine, A Master of Science in Data Analytics, and is a Board-Certified Pharmacotherapy Specialist.

Pat Furlong
Founding President & CEO, Parent Project Muscular Dystrophy

Pat Furlong is the Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest nonprofit organization in the United States solely focused on Duchenne muscular dystrophy (Duchenne). Their mission is to end Duchenne. They accelerate research, raise their voices in Washington, demand optimal care for all young men, and educate the global community.

Duchenne is the most common fatal, genetic childhood disorder. It affects 1:4,600 boys worldwide and has no cure.

When doctors diagnosed her two sons, Christopher and Patrick, with Duchenne in 1984, Pat immersed herself in research, working to understand the pathology of the disorder, the extent of research investment and the mechanisms for optimal care.

In 1994, Pat, together with other parents of young men with Duchenne, founded PPMD to change the course of Duchenne and, ultimately, to find a cure. Today, Pat is considered one of the foremost authorities on Duchenne in the world.

Allison Martin, MS
Director, Regulatory Science and Policy, North America, Sanofi

Allison Martin, MS, is a Director on Sanofi's Regulatory Science and Policy, North America team, where she leads strategic engagement in regulatory policy and advances regulatory science priorities. In this role, she partners with internal and external stakeholders to identify regulatory opportunities and barriers and shape strategies that address them. Allison serves as the regulatory science lead across Cell and Gene Therapies, Rare Disease, Neurology, Vaccines, Pediatrics, Real-World Evidence, and Patient-Focused Drug Development. Prior to joining Sanofi, Allison spent more than a decade in health policy consulting in Washington, DC, and served as a Senior Healthcare Fellow in the U.S. House of Representatives. She holds a Bachelor's degree from Lipscomb University and a Master of Science from Georgetown University.

Fabian Sandoval, MD
President, Emerson Clinical Research Institute

Dr. Fabián Sandoval is a physician, clinical research leader, and nationally recognized health communicator who has dedicated his career to transforming the way clinical research reaches underserved communities. Through his unique integration of medicine, media, community engagement, and research, he has become one of the

country's leading advocates for improving diversity, trust, and access to clinical trials.

As Founder and Chief Executive Officer of Emerson Clinical Research Institute (ECRI), Dr. Sandoval has led the successful conduct and oversight of more than 300 clinical research studies across numerous therapeutic areas. Under his leadership, ECRI has become nationally recognized for its innovative approach to participant recruitment, retention, and community engagement demonstrating that meaningful relationships, culturally relevant education, and trusted communication are essential to advancing medical research. His work continues to challenge traditional research models by bringing clinical trials directly into the communities that have historically been underrepresented.

His commitment to research integrity also led him to serve as Supervisory Research Integrity and Compliance Officer within the U.S. Army Human Research Protections Office in the Office of the Army Surgeon General. In this role, he helped establish and oversee Human Research Protection Programs across Army commands, while providing leadership in protocol development, regulatory oversight, investigator education, and compliance training.

Dr. Sandoval earned his Bachelor of Science in Molecular and Cellular Biology from Marymount University before receiving his Doctor of Medicine degree from the Autonomous University of Guadalajara School of Medicine.

Moderator

Susan C. Winckler, RPh, Esq.
CEO, Reagan-Udall Foundation for the FDA

Susan C. Winckler, RPh, Esq., is CEO of the Reagan-Udall Foundation for the Food and Drug Administration. Prior to accepting the Foundation post, Ms. Winckler served as President of Leavitt Partners Solutions. As President and Chief Risk Management Officer for the Leavitt Partners family of businesses, Ms. Winckler advised corporate executives on policy and business matters. As CEO of the Food & Drug Law Institute, she provided attorneys, regulators, and other stakeholders with a neutral forum to address domestic and global issues. As Chief of Staff for the FDA (2007-2009), Winckler managed the Commissioner's Office, served both Republican and Democratic commissioners as their senior-most staff adviser, analyzed complex policy challenges, and represented FDA with myriad government entities and external stakeholders. Her earlier career service included more than a decade at the American Pharmacists Association. Winckler earned a bachelor's degree from the University of Iowa College of Pharmacy and her law degree magna cum laude from Georgetown University Law Center. She is an APhA Fellow, served as an elected member of the United States Pharmacopeial Convention (USP) Board of Trustees (2015-2020, 2020-2025) and Chair of that Board from 2019 to mid-2025. In 2023, she received the Distinguished Alumni Award of the Food and Drug Administration Alumni Association and, separately, was awarded the Osterhaus Medal for Lifetime Achievement by the Univ. of Iowa College of Pharmacy.

Foundation Staff

Jessica Palfreyman
Senior Program Associate, Reagan-Udall Foundation for the FDA

Jessica Palfreyman joined the Reagan-Udall Foundation for the FDA in March 2023. In her role as Senior Program Associate, she works with the Communication team to support convenings and Expanded Access.

Prior to joining the Foundation, Ms. Palfreyman worked at Intermountain Health, Leavitt Partners, and in the United States Congress.

She has a bachelor's degree from the University of Utah.